Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 14
  1. May 26, 2026 · 08:00 · TSXV: · Routine +

    VVT Med Executes European Rollout with First Italian Patient Treatments Following Strong Clinical Validation

    VVT Med Announces First Patients Treated with VVT's ScleroSafe(TM) System in Italy

    01
  2. May 26, 2026 · 08:00 · VVTM · Routine +

    Operational Milestone Achieved Amidst Regulatory Overhang

    VVT Med Announces First Patients Treated with VVT's ScleroSafe(TM) System in Italy

    02
  3. May 26, 2026 · 07:31 · BPC · Routine +

    Precision Peptide Advances Commercial Launch with MMA Partnership Backing

    The Precision Peptide Company Inc. Places Order for 20,000 BPC-157 Transdermal Patches

    03
  4. May 26, 2026 · 07:30 · BCT · Routine +

    Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

    BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

    04
  5. May 26, 2026 · 07:25 · KNE · Routine −

    Kane Biotech Raises Capital Amidst Revenue Collapse; Dilution Concerns Persist

    Kane Biotech Announces the Oversubscription and Closing of Private Placement Offering

    05
  6. May 26, 2026 · 02:45 · 4503 · Routine +

    Astellas unveils five-year plan to double strategic brand revenue, but execution risks loom large over ambitious pipeline targets.

    Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company

    06
  7. May 25, 2026 · 19:22 · ENBI · Material −

    Entheon’s $40 Million Dream Is Over: Reverse Takeover Terminated, Cash Burn and Shell Risk Return to Center Stage

    Entheon Announces Termination of Business Combination Agreement with Nutravisor

    07
  8. May 25, 2026 · 12:00 · LSL · Neutral

    Revenue Surge Masks Cash Burn Risk as Integration Costs Mount

    LSL Pharma loses $2.8-million in Q1 2026

    08
  9. May 25, 2026 · 09:27 · PCRX · Routine +

    PharmaCorp Rx Advances National Footprint with Definitive Acquisition, Pipeline Execution Validates Growth Strategy

    PharmaCorp Announces Definitive Agreement to Acquire PharmaChoice Canada Bannered Pharmacy in Ontario

    09
  10. May 25, 2026 · 07:00 · GREY · Routine +

    Grey Matters Amends Warrant Terms to Secure Financing as Clinic Expansion Nears; Stock Holds Near Issue Price

    Grey Matters Improves Warrant Terms of Private Placement

    10
  11. May 25, 2026 · 07:00 · LSL · Neutral

    Revenue Surge Masks Integration Costs as LSL Pharma Tests Regulatory Resilience

    LSL PHARMA GROUP REPORTS RECORD REVENUES AND FIRST QUARTER 2026 RESULTS

    11
  12. May 22, 2026 · 19:00 · SKNY · Neutral

    LIR Life Sciences: Operational Progress Masks Lingering Liquidity Risks and Clinical Uncertainty

    LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories

    12
  13. May 22, 2026 · 19:00 · CYTO · Material −

    Cytophage succumbs to insolvency; phage‑therapy pioneer files for bankruptcy as cash‑crunch and failed strategic review wipe out shareholders.

    Cytophage Announces Filings Under the BIA

    13
  14. May 22, 2026 · 17:45 · JOLT · Routine −

    Jolt Health Secures Liquidity Through Discounted Equity Issuance Amidst Price Decline

    Jolt Health arranges debt settlement, financing

    14
← Newer Older →